Corporate News Blog - EDAP Announces Agreement with Theraclion to Market Echopulse HIFU in France
LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for EDAP TMS S.A. (NASDAQ: EDAP) ("EDAP"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=EDAP. The Company announced on October 09, 2017, that it has signed an exclusive agreement with Theraclion to distribute the Echopulse® system in France. Echopulse is utilizing EDAP's proprietary HIFU technology to address breast fibroadenomas and benign thyroid nodules. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on EDAP. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=EDAP
EDAP will provide significant expertise with successful market penetration to Theraclion, through various business models in France.
Partnership Allows Theraclion to Focus Direct Distribution Efforts in Key Markets
Commenting on the agreement, David Caumartin, Chief Executive Officer (CEO) of Theraclion, stated that in France, EDAP has developed a mature sales and logistics organization utilizing business models which enable rapid market penetration where access to reimbursement is slow. Offering a pay-per-use with a mobile solution will be very beneficial in a market like France. Caumartin added that the demand for such a model is high and this partnership allows Theraclion to continue focusing its direct distribution efforts in key markets such as Germany and Asia.
EDAP to Continue Growth Momentum in France by Expanding Portfolio with new HIFU Applications
Marc Oczachowski, CEO of EDAP, mentioned that the Company's sales and marketing team in France have generated major revenue growth in urology, while developing a unique set of offerings with Holmium, HIFU, and ESWL products over the last few years. The Company plans to continue this growth momentum by expanding its portfolio with new HIFU applications such as breast fibroadenomas and benign thyroid nodules, confirming its HIFU leadership in France.
EDAP Partnered with Vituro Health to Add Ablatherm Robotic HIFU
News release suggests that on August 31, 2017, EDAP signed a partnership agreement with Vituro Health LLC, an Alabama-based organization providing HIFU therapy nationwide to patients with prostate cancer. Vituro Health has been offering HIFU Sonablate technology to its patients for years and has decided to add Ablatherm-HIFU to its portfolio to enlarge its offering.
About HIFU
High intensity focused ultrasound (HIFU) is an early stage medical technology that is in various stages of development worldwide to treat a range of disorders. HIFU is only used to treat a single tumor or part of a large tumor.
About EDAP TMS S.A.
Founded in 1979, EDAP is a global leader in therapeutic ultrasound and the most innovative Company in non-invasive treatment for prostate cancer. The Company develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology using ultrasound technology. EDAP markets Ablatherm® for HIFU for prostate tissue ablation in the US and for treatment of localized prostate cancer in the rest of the world.
About Theraclion
Founded in 2004, Theraclion is a French Company specializing in high-tech therapeutic ultrasound equipment. The Company develops, manufactures, and markets the Echopulse® medical device for the non-invasive, outpatient treatment of breast fibroadenomas and benign thyroid nodules. Theraclion is based in Malakoff, France.
Last Close Stock Review
On Tuesday, October 10, 2017, the stock closed the trading session at $3.23, rising 1.32% from its previous closing price of $3.19. A total volume of 23.99 thousand shares have exchanged hands. EDAP TMS' stock price soared 4.19% in the last one month, 2.18% in the past three months, and 30.77% in the previous six months. At Tuesday's closing price, the stock's net capitalization stands at $84.24 million.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
